WASHINGTON (AP) — A decision expected Friday on federal approval for Genentech’s Avastin cancer drug could have ramifications for all companies developing cancer medicines. Genentech made its case for Food and Drug Administration approval of Avastin using a widely debated measure of drug effectiveness that focuses on tumor growth, not patient survival.
